

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 20, 2011**

**iBio, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**000-35023**

(Commission File Number)

**26-2797813**

(IRS Employer Identification No.)

**9 Innovation Way, Suite 100**

**Newark, Delaware 19711**

(Address of principal executive offices, including zip Code)

**(302) 355-0650**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) Appointment of New Director

Effective June 20, 2011, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”) voted to appoint Jules A. Müsing to serve on the Board. Mr. Müsing will be one of the Board’s Class III directors, whose members’ terms expire at the Company’s annual meeting to be held in late 2011.

There is no arrangement or understanding between Mr. Müsing and any other person, pursuant to which Mr. Müsing is to be appointed as a director. Mr. Müsing is not a party to any transactions that would require disclosure under Item 404(a) of Regulation S-K.

In connection with his appointment, Mr. Müsing was granted a stock option to purchase 60,000 shares of the Company's common stock under the Company's stock incentive plan, which shall vest in three equal annual installments beginning on the effective date of Mr. Müsing’s appointment as director, at an exercise price set at the last trading price on the date of appointment.

On June 22, 2011, the Company issued a press release announcing the appointment of Mr. Müsing. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

| <u>Exhibit No.</u> | <u>Description</u>                                |
|--------------------|---------------------------------------------------|
| 99.1               | Press Release of iBio, Inc., issued June 22, 2011 |

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 22, 2011

IBIO, INC.

By: /s/ Douglas Beck

Douglas Beck  
Chief Financial Officer

---

## **Jules A. Müsing Joins iBio's Board of Directors**

NEWARK, Del.--(BUSINESS WIRE)-- iBio, Inc. (NYSE AMEX: IBIO) announced today the appointment of Jules A. Müsing, formerly a senior executive at Johnson & Johnson, to iBio's Board of Directors.

In the course of his career at Johnson & Johnson, Mr. Müsing was responsible for worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances. This included the establishment of new scientific and product collaborations in various therapeutic areas, the negotiation of licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide, and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets. Prior to moving into that role, Mr. Müsing was Vice President Marketing International for the Janssen Pharmaceutica Group of Companies Worldwide; President of Pitman-Moore, Inc., a U.S.-based Johnson & Johnson company; Managing Director of Janssen Pharmaceutica in Portugal; President of Serono, Inc. in the U.S. and Executive Vice President with responsibilities for North and South America; Member of the Board of Ortho Biotech, Inc.; and Managing Director of Ortho Biotech in France (a Johnson & Johnson affiliate).

"In addition to undertaking normal Board responsibilities, Jules has indicated an interest in playing an active role in the further development of iBio's business and licensing programs," said Robert B. Kay, iBio's Executive Chairman and Chief Executive Officer. "I expect his experience and relationships to significantly advance our commercialization activities."

### **About iBio, Inc.**

iBio develops and offers product applications of its iBioLaunch™ platform, offering collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. Further information is available at: [www.ibioinc.com](http://www.ibioinc.com).

---

## **Forward-Looking Statements**

*Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.*

### **Contact:**

iBio, Inc.

Corporate:

Robert Erwin, President

302-355-2335

[rerwin@ibioinc.com](mailto:rerwin@ibioinc.com)

or

Investor Contact:

Laurie S. Roop, 302-355-9452

[ir@ibioinc.com](mailto:ir@ibioinc.com)

---